Alpha Cognition Inc
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $196.9M
- Price
- $9.04
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.67%
- Volume
- 40.4K
About
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Quick stats
Shares outstanding21.8M
Computed float21.2M
Float / shares97.5%
Cash runway (months)11.3
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001655923
AI Summary
AI-generated1/29
minorbullishclinical trial
Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress
Alpha Cognition will present new clinical and real-world data on ZUNVEYL (benzgalantamine) at the ASCP Annual Meeting (Oct 29-Nov 1, 2026) and the NEI Fall Congress (Nov 5-8, 2026).
Eleven posters span cognition, function, neuropsychiatric symptoms, sleep, GI tolerability, treatment patterns and psychotropic medication utilization in long-term care Alzheimer's patients, including BEACON study analyses.
The data presentations support the company's evidence-building for commercial uptake of ZUNVEYL but contain no new primary efficacy results or regulatory catalysts.